The GLP-1 Drug Market was valued at USD 19.2 billion in 2023. The industry is projected to grow from USD 23.2 billion in 2024 to USD 88.2 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 21.00% during the forecast period (2024 - 2032). The increasing prevalence of diabetes and preference for non-insulin therapies are the primary drivers propelling the market's expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Obesity is a worldwide epidemic related to various health problems, including type 2 diabetes, cardiovascular infections, and certain tumors. By focusing on obesity, GLP-1 medications can address a significant unmet clinical need and add to further developed general well-being results. GLP-1 drugs have demonstrated potential in controlling blood sugar levels and advancing weight decrease. Their strategy for activity includes deferred stomach evacuation and reducing appetite, which are beneficial in the control of diabetes and weight gain. This double treatment benefit improves the offer of GLP-1 drugs in the treatment of weight.
Additionally, worldwide accessible GLP1RAs are suggested for utilization in cases when escalation of therapy for type 2 diabetes must occur following metformin and lifestyle modification. With the exception of vildagliptin, they can be implemented properly with all other glucose-lowering therapies. Weekly subcutaneous GLP1RA dulaglutide (Trulicity) lowers HbA1c while also promoting weight reduction and cardiorenal protection. Many patients can achieve and maintain their goal HbA1c with dulaglutide therapy without the need for insulin or sulfonylureas, which removes the risk of hypoglycemia. In cases when cerebrovascular illness other than heart failure or renal disease is the predominant condition, GLP1RAs are preferred over SLGT2 inhibitors due to their increased ability to reduce weight.
In certain nations, patients who fulfill particular legal requirements may get full funding for dulaglutide. According to guidelines from New Zealand, for example, all patients with HbA1c levels above target should be offered GLP1RAs, particularly if using them would further reduce cardiovascular risk and allow for the reduction or cessation of other therapies that increase the risk of weight gain or hypoglycemia.
Despite diabetic management, GLP-1 medications have demonstrated cardiovascular advantages, such as lowering the risk of major adverse cardiovascular events (MACE) such as heart attacks, strokes, and cardiovascular deaths. Healthcare professionals and patients alike are coming to appreciate and acknowledge its cardioprotective benefits more. Cardiovascular disease is the primary cause of illness and death among people with diabetes. GLP-1 medications fill a major hole in the treatment options available to this patient population by providing cardiovascular protection, making them the go-to choices for controlling diabetes and lowering cardiovascular risk. As per the (IDF), more than 537 million grown-up individuals overall will have diabetes in 2021, and this proportion is projected to develop by 643 million by 2030. Over the long run, numerous changes have been made to the GLP-1RA prescription or the formulations that are being made because of more prominent advancement, thus driving the GLP-1 Drug market revenue.
Based on Type, the GLP-1 Drug Market segmentation includes long-acting GLP-1 drugs and short-acting GLP-1 drugs. In 2023, the long-acting GLP-1 drug segment dominated the market. Long-acting GLP-1 prescriptions have a less successive dosage plan, which might increase patient adherence to treatment and diligence because they diminish the probability of missed dosages or treatment stopping from infusion fatigue. Since long-acting GLP-1 drugs keep up with plasma focuses for a longer amount of time, blood glucose in the executives is more consistent over the day. Better glycemic results for people with type 2 diabetes might result from this.
The short-acting GLP-1 drug category is anticipated to be the fastest growing. Short-acting GLP-1 meds can be taken not long before feasts to match food intake. This flexibility further develops comfort and adherence by empowering patients to customize their drug to accommodate their remarkable dietary habits and lifestyles.
Figure 1: GLP-1 Drug Market by Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on Application, the GLP-1 Drug Market segmentation includes Type 2 Diabetes (T2DM), Obesity, Non-alcoholic Steatohepatitis (NASH), Alzheimer's Disease (AD), and Cardiovascular and Cerebrovascular Diseases (CVD). In 2023, the Type 2 Diabetes (T2DM) category generated the most income. Strong glucose-lowering medications known as GLP-1s enhance the management of glucose by increasing the creation of insulin and preventing glucagon release. They assist in lowering fasting plasma glucose, postprandial glucose excursions, and HbA1c levels in T2DM patients. A decrease in substantial adverse coronary incidents, including heart attacks, strokes, and cardiac deaths, has been shown to occur in response to several GLP-1 medications, which have shown cardiovascular advantages beyond glucose management. For T2DM patients who are more likely to experience cardiovascular problems, these cardioprotective benefits are very important.
The GLP-1 Drug Obesity segment market is anticipated to grow the fastest during the forecast period. GLP-1 medications not only assist individuals to gain weight but also boost their lipid profile, blood pressure, and glycemic management. Those who are obese and more likely to develop digestive issues and heart attacks will benefit most from these benefits.
The study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American GLP-1 Drug market will dominate this market. All over the world, diabetes prevalence is greatest in North America, mainly the United States. A huge group of patients who require efficient therapies, such as GLP-1 medications, is brought about by the rising prevalence of type 2 diabetes in the area. North America is dedicated to popular medical systems and a sophisticated medical system that makes cutting-edge therapies more accessible. This speeds up market expansion and makes it easier for new treatments like GLP-1 medications to be adopted.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: GLP-1 Drug Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's GLP-1 Drug market accounts for the second-largest market share. Europe has state-of-the-art medical facilities that give access to cutting-edge therapies and extensive security. This encourages both patients and physicians to use GLP-1 medications, propelling market expansion. Further, the German GLP-1 Drug market held the largest market share, and the UK GLP-1 Drug market was the fastest-growing market in the European region.
The Asia-Pacific GLP-1 Drug Market is expected to grow at the fastest CAGR from 2024 to 2032. Additionally, numbers of obese people around the area continue to rise, especially in nations that are experiencing fast economic development. Being overweight is a major risk factor for type 2 diabetes. Hence, weight-management techniques like GLP-1 drugs are becoming more and more necessary. Moreover, China’s GLP-1 Drug market held the largest market share, and the Indian GLP-1 Drug market was the fastest-growing market in the Asia-Pacific region.
GLP-1 Drug Key Market Players & Competitive Insights
The industry's leading players will keep spending a lot of money on research and development to increase their product lines, which will propel the GLP-1 Drug market's growth. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the GLP-1 Drug industry must offer reasonably priced products and services.
One of the main strategies manufacturers use in the worldwide GLP-1 Drug market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. The GLP-1 Drug industry has recently provided some of the largest medical advantages. Major players in the GLP-1 Drug market, including Eli Lilly and Company, AstraZeneca, Pfizer, Sanofi, GSK, Novo Nordisk, Gan & Lee Pharmaceuticals, Boehringer Ingelheim, Tonghua Dongbao Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Shanghai Renhui Biopharmaceutical Co., Ltd., Shanghai East China Pharmaceutical Machinery Co., Ltd., and others, are making investments in R&D activities in an effort to boost market demand.
A pharmaceutical firm called Eli Lilly and Co. (Lilly) finds, develops, and sells items for the benefit of people. The firm supplies medications for musculoskeletal issues, health for men, diabetes, endocrinology, tumors, neurological issues, autoimmune diseases, and cardiovascular illnesses. The firm uses independent wholesale distributors to market its pharmaceutical health items. Lilly carries out research and development operations in order to find and provide novel medications. Through sales reps and marketing partnerships with other pharmaceutical businesses, it advertises its medications. The (FDA) in the US approved two more doses of Eli Lilly and Company's GLP-1 receptor agonist medication, Trulicity (dulaglutide), in September 2020. Trulicity is suggested for the treatment of type-2 diabetes in adults.
The medical company Novo Nordisk AS, a division of Novo Holdings AS, devoted itself to the exploration, creation, and distribution of natural drugs. It concentrates on creating medications to manage diabetes and other severe persistent illnesses such as weight gain, uncommon blood and hormonal conditions, hemophilia, and problems affecting an individual’s growth hormone (HGH). Pre-filled insulin delivery systems, glucagon hypokits, cartridges, needles, vials, insulin, recombinant medications for hemophilia, glucagon, and oral antidiabetic agents are among the products offered by the company. The European Medical Administration (EMA) authorized Novo Nordisk A/S, a medical company with headquarters in Denmark, to acquire marketing permission for Rybelsus (semaglutide). This oral GLP-1 receptor agonist was used to treat Type 2 diabetes in April 2020.
Key Companies in the GLP-1 Drug market include
GLP-1 Drug Industry Developments
March 2023: The NHS recognized Wegovy, a weight reduction infusion that contains semaglutide. Glucagon-like peptide-1 (GLP-1) mimicking is how wegovy reduces appetite. Many thousands of obese individuals in England will soon have access to Wegovy, an injectable that contains semaglutide and helps lose weight.
May 2022: Eli Lilly and Company's Mounjaro (tirzepatide) injectable has been approved by the US (FDA) to be used in addition to diet and exercise. In adults with type 2 diabetes, it is intended to improve glycemic control. Mounjaro is a single-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor and a glucose-dependent insulinotropic polypeptide (GIP) that is released once a week.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 19.2 Billion |
| Market Size 2024 | USD 23.2 Billion |
| Market Size 2032 | USD 88.2 Billion |
| Compound Annual Growth Rate (CAGR) | 21.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled | Eli Lilly and Company, AstraZeneca, Pfizer, Sanofi, GSK, Novo Nordisk, Gan & Lee Pharmaceuticals, Boehringer Ingelheim, Tonghua Dongbao Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Shanghai Renhui Biopharmaceutical Co., Ltd., and Shanghai East China Pharmaceutical Machinery Co., Ltd. |
| Key Market Opportunities | ·        Development of next-generation therapies and growing focus on patient-centric solutions |
| Key Market Dynamics | ·        Increasing prevalence of diabetes and preference for non-insulin therapies |
Frequently Asked Questions (FAQ) :
The GLP-1 Drug Market size was valued at USD 19.2 Billion in 2023.
The global market is projected to grow at a CAGR of 21.00% during the forecast period 2024-2032.
North America had the largest share of the global market.
The key players in the market are Eli Lilly and Company, AstraZeneca, Pfizer, Sanofi, GSK, Novo Nordisk, Gan & Lee Pharmaceuticals, Boehringer Ingelheim, Tonghua Dongbao Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Shanghai Renhui Biopharmaceutical Co., Ltd., and Shanghai East China Pharmaceutical Machinery Co., Ltd., among others.
The Long-acting GLP-1 Drug category dominated the market in 2023.
Type 2 Diabetes (T2DM) is the largest share of the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
